Literature DB >> 9604859

Losartan in Cushing's syndrome.

S Zacharieva1, M Orbetzova, E Natchev, J Vergilova, M Andrewa, M Wipperrnann, S Torbova, D Tzingilev, P Angelova-Gateva.   

Abstract

Eleven patients with Cushing's syndrome were included in the study. They maintained their usual sodium intake and received a single oral dose of 50 mg of the angiotensin II antagonist receptor losartan for 3 days. Losartan treatment resulted in stimulation of active renin and decrease of plasma and urinary kallikrein activity. Both systolic and diastolic blood pressure decreased independently of baseline level of active renin. The relationship between kallikrein and renin-angiotensin system are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9604859     DOI: 10.1358/mf.1998.20.2.472459

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  6 in total

1.  Cushing's syndrome: all variants, detection, and treatment.

Authors:  Susmeeta T Sharma; Lynnette K Nieman
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

Review 2.  Glucocorticoid excess and hypertension.

Authors:  Smita Baid; Lynnette K Nieman
Journal:  Curr Hypertens Rep       Date:  2004-12       Impact factor: 5.369

Review 3.  Hypertension in patients with Cushing's disease: pathophysiology, diagnosis, and management.

Authors:  Alan Sacerdote; Karolina Weiss; Tri Tran; Begum Rokeya Noor; Samy I McFarlane
Journal:  Curr Hypertens Rep       Date:  2005-06       Impact factor: 5.369

Review 4.  Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications.

Authors:  G Arnaldi; T Mancini; G Tirabassi; L Trementino; M Boscaro
Journal:  J Endocrinol Invest       Date:  2012-04       Impact factor: 4.256

Review 5.  Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events.

Authors:  Laurence Fardet; Bruno Fève
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

6.  Changes in systolic blood pressure in dogs with pituitary dependent hyperadrenocorticism during the first year of trilostane treatment.

Authors:  Paula García San José; Carolina Arenas Bermejo; Daniel Alonso-Miguel; Irene Clares Moral; Pedro Cuesta-Alvaro; María Dolores Pérez Alenza
Journal:  J Vet Intern Med       Date:  2020-12-04       Impact factor: 3.175

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.